Evogene Finalizes Highly Dilutive $2.9M ATM Offering Amidst Delisting and Going Concern Risks

summarizeSummary

Evogene has finalized a highly dilutive At-The-Market (ATM) offering to sell up to $2.9 million in shares, a critical move to address liquidity and "going concern" issues while facing Nasdaq delisting.

check_boxKey Events

• ATM Offering Finalized

  Evogene has entered into a sales agreement to sell up to $2.9 million of ordinary shares through an At-The-Market (ATM) offering, finalizing terms of a program initiated on June 11, 2026.

• Significant Potential Dilution

  If fully utilized, the offering could result in the issuance of approximately 4.9 million shares, representing a potential dilution of over 40.5% to existing shareholders.

• Addresses Liquidity & Going Concern

  The proceeds are intended for research and development, working capital, and general corporate purposes, directly addressing the company's limited cash resources and auditor-identified 'going concern' assessment.

• Nasdaq Delisting Context

  This capital raise occurs while Evogene is non-compliant with Nasdaq's minimum bid price rule, with a deadline of September 28, 2026, to regain compliance.

auto_awesomeAnalysis

This 424B5 prospectus supplement finalizes the terms of the At-The-Market (ATM) offering, allowing Evogene to sell up to $2.9 million in ordinary shares. This represents a substantial capital raise, potentially diluting existing shareholders by over 40%. The offering is critical for the company's liquidity and operations, especially given its previously disclosed "going concern" issues and ongoing Nasdaq delisting concerns due to its low share price. The proceeds are intended for general corporate purposes, including R&D and working capital, highlighting the urgent need for funds to sustain operations.